Nanoparticle vaccine that blocks nicotine from reaching the
This technology is a nanoparticle-based vaccine designed to trigger the immune system to produce antibodies against nicotine, so that when a person smokes or uses tobacco, the antibodies bind to nicotine molecules in the bloodstream and prevent them from reaching the brain. The nanoparticle has a polymer core wrapped in a lipid shell, with nicotine-mimicking molecules (haptens) displayed on its surface to train the immune system to recognize nicotine as a foreign threat. Multiple immune-stimulating components are built into the same particle to maximize the antibody response. The goal is a pharmaceutical intervention—likely an injectable vaccine—that reduces or eliminates the rewarding effect of nicotine, helping people quit smoking or preventing addiction from forming.
What you could build
A prescription anti-nicotine vaccine, administered as an injection series, sold to healthcare providers and payers as a cessation therapy or preventive treatment—targeting smoking cessation clinics, primary care networks, and potentially military/government health programs.
Who in Virginia should care
Virginia's large military and veteran population, combined with defense health contractors and academic medical centers like UVA and VCU, represents a natural clinical trial and early-adoption environment for smoking cessation therapeutics.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Chenming ZHANG, Zongmin ZHAO, Yun HU
- Granted
- March 22, 2022
- Status
- Granted patent
- Patent number
- 11278608
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.